Tobacco use, determinants and effects on treatment among persons living with HIV/AIDS at Military Hospital in Makurdi, Benue State, Nigeria
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20221209Keywords:
Tobacco use, Prevalence, Determinants, Effects on treatment, Military Hospital, NigeriaAbstract
Background: Tobacco use is a leading avertable cause of premature death globally. It is commonly used among PLWHIV and with mortality tripling compared to the general population. Its impact on them is multifactorial. This study aims to assess the prevalence, determinants and effects of tobacco and its related products on treatment among persons living with HIV at a military hospital in Makurdi, Benue State, Nigeria
Methods: The study was among HIV positive clients ≥18 years who have accessed care for ≥12 months at Nigerian air force hospital, Makurdi of Benue state, Nigeria. A descriptive cross-sectional study was done using adopted WHO ASSIST (V3.0) questionnaire. Simple random sampling method was used to select 700 clients studied.
Results: About 138(19.7%) have used Tobacco products and 66 (9.4%) in past 3 months of which 10 (90.3%) were mild users. Of those that ever-used tobacco 114 (82.6%) used Tobacco and other substances; 90 (79.0%) Alcohol, 73 (64.0%) Kola nut, 8 (7.0%) Cannabis and 5 (4.4%) Cocaine. Determinants of use were male gender (AOR 0.23; 95% CI 0.15-0.35) and earning <18,000 (AOR 2.23; 95% CI 1.05-4.70). There were no associations of tobacco use with viral load and CD4 count.
Conclusions: Prevalence of Tobacco use was higher than general population. Male gender and low socioeconomic status were determinants of use of tobacco. Addressing this menace of tobacco use is an important political and public health issue.
References
A history of the HIV/AIDS epidemic with emphasis on Africa. Available at: https://www.un.org/en/ development/desa/population/events/pdf/expert/5/UNAIDS_WHO. Accessed on 20 February 2021.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://aidsinfo.nih.gov/guidelines. Accessed on 20 February 2021.
WHO warns countries of growing risk of HIV drug resistance. Available at: https://www.who.int/hiv/ media centre/news/warning-hiv-drug-resistance/en/. Accessed on 20 February 2021.
Hamers RL, Sigaloff KCE, Kityo C, Mugyenyi P, de Wit TFR. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS. 2013;8(1):19-26.
WHO HIV Drug Resistance Report 2012. Available at: www.who.int/hiv/pub/drugresistance/report2012/en/. Accessed on 20 February 2021.
Eriksen M, Mackay J, Ross H. The Tobacco Atlas. Available at: https://tobaccoatlas.org. Accessed on 20 February 2021.
Calvo M, Laguno M, Martinez M, Martinez E. Effects of tobacco smoking on HIV-infected individuals. Aids Rev. 2015;17(1):47-55.
Kariuki W, Manuel JI, Kariuki N. HIV and smoking: Associated risks and prevention strategies. HIV/AIDS. 2016;8:17-36.
Lifson AR, Neuhaus J, Arribas JR. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100:189-93.
Aniwada EC, Uleanya ND, Ossai EN, Nwobi1 EA, Anibueze M. Tobacco use: prevalence, pattern, and predictors, among those aged 15-49 years in Nigeria, a secondary data analysis. Tob Induc Dis. 2018;16(7):1-8.
Edelman EJ, Tetrault JM, Fiellin DA. Substance use in older HIV-infected patients. Curr Opin HIV AIDS. 2014;9(4):317-24.
Helleberg M, Afzal S, Kronborg G. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727-34.
The alcohol, smoking and substance involvement screening test. Available at: https://www.who.int/ publications/i/item/978924159938-2. Accessed on 15 February 2021.
Yunusa M, Obembe A, Ibrahim T, Njoku C. Prevalence and specific psychosocial factors associated with substance use and psychiatric morbidity among patients with HIV infection at Usmanu Danfodiyo University Teaching Hospital, Sokoto State, Nigeria. Afr J Drug Alcohol Stud. 2011;10(1):45-9.
Adeyemo F, Ohaeri B, Okpala PU, Oghale O. Prevalence of drug abuse amongst university students in Benin City, Nigeria. Public Heal Res. 2016;6(2):31-7.
Prevalence of tobacco smoking. Available at: http://www.who.int/gho/tobacco/use/en/. Accessed on 15 February 2021.
Global Adult Tobacco Survey. Available at: https://www.who.int/tobacco/ surveillance/survey/ gats/nigeria_country_report.pdf. Accessed on 15 February 2021.
Joffer J, Burell G, Bergström E. Predictors of smoking among Swedish adolescents. BMC Public Health. 2014;14:1296.
Palipudi KM, Sinha DN, Choudhury S, Zaman MM, Asma S, Andes L, et al. Predictors of tobacco smoking and smokeless tobacco use among adults in Bangladesh. Indian J Cancer. 2012;49(4):387-92.
Brazil National Cancer Institute. Global Adult Tobacco Survey Brazil 2008. Available at: http://www.who.int/ tobacco/surveillance/en_tfi_gats_2010_brazil.pdf. Accessed on 15 February 2021.
Doku D, Koivusilta L, Raisamo S, Rimpela A. Do socioeconomic differences in tobacco use exist also in developing countries? A study of Ghanaian adolescents. BMC Public Health. 2010;8(10):758.
Simetin P, Kern J, Kuzman M, Pfortner TK. Inequalities in Croatian pupils’ risk behaviours associated to socioeconomic environment at school and area level: a multilevel approach. Soc Sci Med. 2013; 98:154-61.
Hosseinpoor AR, Parker LA, Tursan d’Espaignet E, Chatterji S. Social determinants of smoking in low-and middle-income countries: results from the world health survey. PLoS One. 2013;6:e20331.
Kumar S, Jin M, Ande A. Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: Role of cytochrome P450 isozymes. Exp Opin Drug Metab Toxicol. 2010;8:1363-75.
Zhao L, Li F, Zhang Y. Mechanisms and genes involved in enhancement of HIV infectivity by tobacco smoke. Toxicology. 2010;278:242-8.
